

1 **Creld2 function during unfolded protein response is essential for liver**  
2 **metabolism homeostasis**

3

4 Paul Kern<sup>1,2\*</sup>, Nora R. Balzer<sup>1</sup>, Franziska Bender<sup>2</sup>, Alex Frolov<sup>1</sup>, Klaus Wunderling<sup>3</sup>,  
5 Jan-Peter Sowa<sup>4,5</sup>, Lorenzo Bonaguro<sup>6,7</sup>, Thomas Ulas<sup>6,7</sup>, Christoph Thiele<sup>3</sup>, Joachim  
6 L. Schultze<sup>6,7</sup>, Ali Canbay<sup>4,5</sup>, Reinhard Bauer<sup>2</sup>, Elvira Mass<sup>1\*</sup>

7

8 1 Developmental Biology of the Immune System, Life & Medical Sciences (LIMES)  
9 Institute, University of Bonn, 53115 Bonn, Germany

10 2 Developmental Genetics & Molecular Physiology, Life & Medical Sciences (LIMES)  
11 Institute, University of Bonn, 53115 Bonn, Germany

12 3 Biochemistry & Cell Biology of Lipids, Life & Medical Sciences (LIMES) Institute,  
13 University of Bonn, 53115 Bonn, Germany

14 4 Department of Gastroenterology, Hepatology and Infectious Diseases, University  
15 Hospital Magdeburg, 39120 Magdeburg, Germany

16 5 Department of Medicine, Ruhr University Bochum, University Hospital  
17 Knappschaftskrankenhaus Bochum, 44892 Bochum, Germany

18 6 Genomics and Immunoregulation, Life & Medical Sciences (LIMES) Institute,  
19 University of Bonn, 53115 Bonn, Germany

20 7 Platform for Single Cell Genomics and Epigenomics at the German Center for  
21 Neurodegenerative Diseases and the University of Bonn, 53127 Bonn, Germany

22

23 \*corresponding author: [emass@uni-bonn.de](mailto:emass@uni-bonn.de), [kern.p@uni-bonn.de](mailto:kern.p@uni-bonn.de)

24

25 Keywords: ER stress, UPR, NASH, liver steatosis

26

27 **Abstract**

28 The unfolded protein response (UPR) is associated with the hepatic metabolic function,  
29 yet it is not well understood how endoplasmic reticulum (ER) disturbance might  
30 influence metabolic homeostasis. Here, we describe the physiological function of  
31 Cysteine-rich with EGF-like domains 2 (Creld2), previously characterized as a  
32 downstream target of the ER-stress signal transducer Atf6. To this end we generated  
33 *Creld2*-deficient mice and induced UPR by injection of tunicamycin. Creld2 augments  
34 protein folding and creates an interlink between the UPR axes through its interaction  
35 with proteins involved in UPR. Thereby, Creld2 promotes tolerance to ER stress and  
36 recovery from acute stress. *Creld2*-deficiency leads to a dysregulated UPR, and  
37 causes the development of hepatic steatosis during ER stress conditions. Moreover,  
38 Creld2 enhancement of the UPR assists in the regulation of energy expenditure.  
39 Furthermore, we observed a sex dimorphism in humans with fatty liver disease, with  
40 only males showing an accumulation of CRELD2 protein in the liver. These results  
41 reveal a Creld2 function at the intersection between UPR and metabolic homeostasis  
42 and suggest a mechanism in which chronic ER stress underlies fatty liver disease in  
43 males.

44

45 **Introduction**

46 The Cysteine-rich with EGF-like domains (Creld) protein family consists of two  
47 members – Creld1 and Creld2 – and is highly conserved across species [1,2]. The  
48 domain structure between these proteins is almost identical with the only difference of  
49 transmembrane domains being present in Creld1, but lacking in Creld2 [3]. This leads  
50 to the distinct localization and functions of these proteins within a cell: Creld1 is  
51 proposed to be anchored in the endoplasmic reticulum (ER) membrane with its  
52 domains facing the cytoplasm [4], although a plasma membrane bound form facing the

53 extracellular matrix has been predicted as well [1]. We previously characterized the  
54 function of *Creld1* being essential for heart development in mice [4]. *Creld2* is localized  
55 predominantly within the ER, can be secreted [3], and has been characterized as a  
56 marker for kidney disease in urine [5] and for prosthetic joint infections in synovial fluid  
57 [6]. However, the physiological role of *Creld2* *in vivo* remains elusive.

58         Several *in vitro* studies have identified *Creld2* as an ER-stress inducible gene,  
59 whose expression is dependent on the ER stress sensor activating transcription factor  
60 6 (*Atf6*) activity [7,8]. Yet, for full gene expression induction the combined activity of all  
61 three ER stress sensors, namely inositol requiring enzyme 1 (*Ire1*), protein kinase  
62 RNA-activated (PKR)-like ER kinase (*Perk*) and *Atf6*, is required [9,10]. ER stress is  
63 characterized by an accumulation of mis- and/or unfolded proteins in the ER lumen.  
64 Consequently, cells activate the unfolded protein response (UPR), a network of  
65 signaling pathways that collectively aims at decreasing ER protein load by broad  
66 inhibition of protein synthesis and at the same time promotes the activation and  
67 production of proteins that increase the protein folding capacity and protein  
68 degradation. The latter include chaperones, shuttling proteins that promote secretion  
69 of proteins out of the ER and ER-associated protein degradation (ERAD) components  
70 [11,12].

71         The ER luminal domains of the ER stress sensors are bound and thereby  
72 inactivated by the chaperone Grp78 (glucose-regulated protein 78, also known as heat  
73 shock protein A5 (*Hspa5*)). Upon ER stress Grp78 is sequestered by the accumulation  
74 of proteins in the ER lumen, causing the activation of the three sensors. *Perk* dimerizes  
75 and is activated by trans-autophosphorylation of its kinase domains, leading to  
76 translational inhibition through *eIF2 $\alpha$*  phosphorylation. This directly enhances the  
77 translation of DNA-damage-inducible 34 (*Gadd34*) and CAAT/enhancer-binding  
78 protein (C/EBP) homologous protein (*Chop*). While *Gadd34* serves as a feedback loop

79 to dephosphorylate eIF2 $\alpha$  allowing the cell to recover from translational inhibition,  
80 increased Chop expression may trigger cell death due to unresolved ER stress. The  
81 kinase Ire1 undergoes autophosphorylation resulting in splicing of the *X-box binding*  
82 *protein 1 (sXbp1)* mRNA producing an active transcription factor, which induces the  
83 transcription of chaperones and ERAD pathway components. ER-membrane bound  
84 Atf6 is proteolytically cleaved and translocates to the nucleus where it activates target  
85 genes including ERAD components, chaperones, and major genes involved in lipid  
86 metabolism [13].

87 The liver is a highly secretory organ and serves frequently as the tissue to  
88 investigate ER stress. Previous studies demonstrate that induction of ER stress leads  
89 to hepatic steatosis through the direct and indirect regulation of lipid metabolism [14–  
90 16]. On the contrary, in genetic and dietary models of obesity, a link between hepatic  
91 stress and insulin resistance has been established [17–20], suggesting that the  
92 accumulation of lipids within hepatocytes and the resulting hepatocellular damage is  
93 linked to dysfunction of the ER. Therefore, the arrow of causality between  
94 hepatosteatosis and ER stress remains unclear.

95 Intriguingly, *Atf6* knockout mice do not exhibit developmental defects or any  
96 obvious phenotypes at steady state, yet show an abrogated response to ER stress  
97 under challenge with the ER stressor tunicamycin (Tm), which macroscopically  
98 manifests in the development of liver steatosis [15,21]. Further, Atf6 was shown to  
99 regulate physiological responses under diet-induced obesity [22], suggesting the UPR  
100 being upstream of hepatosteatosis.

101 To address the function of *Creld2* within the Atf6 signaling pathway and its  
102 possible role in hepatic pathophysiology, we generated a *Creld2* knockout mouse and  
103 characterized its role during ER stress challenge and diet-induced obesity in the liver.  
104 We show that *Creld2* deficiency promotes the development of liver steatosis when

105 mice are burdened with ER stress, while lack of Creld2 ameliorates diet-induced  
106 hepatosteatosis. Further, we identify Creld2 protein interaction partners that are  
107 involved in ER-stress release, thereby placing Creld2 functionally into the cellular  
108 stress response of a cell *in vivo*. The conserved function of Creld2 across species is  
109 supported by the accumulation of CRELD2 in male patients with non-alcoholic  
110 steatohepatitis (NASH).

111

## 112 **Results**

113 To investigate Creld2 function *in vivo* we generated a *Creld2*-knockout mouse model  
114 by replacing the endogenous locus with an enhanced green fluorescent protein (eGFP)  
115 (*Creld2<sup>eGFP/eGFP</sup>*, Figure 1A), allowing the use of both *Creld2<sup>WT/eGFP</sup>* and *Creld2<sup>eGFP/eGFP</sup>*  
116 as reporter mice for *Creld2* expression. We confirmed ubiquitous protein expression  
117 [23] as well as lack of Creld2 expression in *Creld2<sup>eGFP/eGFP</sup>* mice in various tissues via  
118 Western blot (Figure 1B). *Creld2<sup>eGFP/eGFP</sup>* mice were born in Mendelian ratios (Figure  
119 1C) and were viable. In concordance with studies of *Atf6<sup>-/-</sup>* mice, which do not show  
120 any anomalous phenotype during unchallenged conditions [15], young *Creld2<sup>eGFP/eGFP</sup>*  
121 mice (1-2 month-old) did not show differences in body and liver weight (Figure 1D, E)  
122 or changes in tissue morphology as assessed histologically via hematoxylin-eosin (HE)  
123 and Masson-Goldner Trichrome (MGT) stain (Figure 1F).

124

125 Given that *Creld2* is induced by *Atf6* and that *Atf6* was shown to regulate responses  
126 under high-fat diet induced obesity [22], we asked whether Creld2 is involved in  
127 regulating metabolic responses due to prolonged accumulation of lipids in hepatocytes.  
128 To induce the development of fatty liver, we placed 8-week-old *Creld2<sup>eGFP/eGFP</sup>* males  
129 and wildtype littermates on control diet (CD) or high-fat diet (HFD). To test whether  
130 animals could recover from hepatosteatosis, we split the HFD group after 8 weeks with

131 one group remaining on HFD for 4 more weeks and one group being switched to CD  
132 (HFD>CD, Figure 2A). Measuring mice body weights, we found that *CreId2<sup>eGFP/eGFP</sup>*  
133 animals on CD gained less weight over time (Figure 2B). Similarly, after 8-12 weeks  
134 on HFD *CreId2<sup>eGFP/eGFP</sup>* showed reduced body weights when compared to littermate  
135 controls (Figure 2B), but developed insulin resistance as measured by the homeostatic  
136 model assessment indices of insulin resistance (HOMA-IR) after 8 weeks (Figure 2C).  
137 Moreover, both genotypes increased the total tissue weight of livers and epididymal  
138 white adipose tissue (eWAT) (Figure S1A) indicating that *CreId2<sup>eGFP/eGFP</sup>* animals were  
139 not protected from diet-induced obesity.

140 Histological assessment of the liver showed an increased oil-red-O (ORO)  
141 staining in HFD-fed mice (Figure S1B, C), indicating increased neutral lipid storage.  
142 This was accompanied by a decrease in PAS signal (Figure S1D, E) confirming diet-  
143 induced hepatosteatosis in both genotypes. Accumulation of lipids in general, which  
144 resulted mainly from TAG and DAG accumulation, was confirmed by shotgun  
145 lipidomics (Figure 2D). *CreId2<sup>eGFP/eGFP</sup>* livers contained generally less lipids (Figure  
146 2D), which could account for the on average lower liver weight (Figure S1A). HFD did  
147 not induce a fibrotic phenotype, nor did it affect liver function as assessed by MGT  
148 staining (Figure S1F, G) and alanine aminotransferase (ALT) concentrations in the  
149 serum (Figure S1H), respectively. When the HFD groups were switched to CD, their  
150 body, liver and eWAT weight returned to the level of animals that were kept on CD  
151 (Figure 2B, S1A). Further, ORO and PAS signals as well as the amount of lipids  
152 returned to baseline levels in both genotypes (Figure 2D, S1B-E). Together, our data  
153 indicate that on organismal and tissue level *CreId2*-deficient mice responded similarly  
154 to wildtype mice upon diet-induced obesity and lipid uptake as well as mobilization of  
155 lipids after a diet switch from HFD to CD.

156 To test whether lipid accumulation or subsequent lipid mobilization triggered  
157 differential cellular stress responses in *Creld2<sup>eGFP/eGFP</sup>* and littermate control livers, we  
158 performed RNA-sequencing (RNA-seq) after 12 weeks on diet (Figure 2E, F, S1I). We  
159 made use of Construction of Co-expression network analysis 2 (CoCena<sup>2</sup>) to cluster  
160 the top 5000 variable genes into distinct modules based on the expression patterns  
161 across the two genotypes and three conditions (Figure 2E).

162 CoCena identified the gold module (721 genes) with globally upregulated genes  
163 in *Creld2<sup>eGFP/eGFP</sup>* livers showing highest differences after HFD>CD diet (Figure 2E).  
164 Gene Ontology (GO) and KEGG enrichment analyses indicated an enrichment for  
165 cytoplasmic translation as well as ribosome proteins and ribosome production (Figure  
166 2F). Additionally, the maroon module that showed an induction of 141 genes in  
167 *Creld2<sup>eGFP/eGFP</sup>* livers after HFD returned 'apoptosis' as Hallmark term (Figure 2E)  
168 including *Bcl2l1*, *Gch1* and *Gsr* (Figure 2F), suggesting that knockout livers may  
169 experience more apoptosis than wildtype controls. This notion was supported by an  
170 increase of ceramides in *Creld2<sup>eGFP/eGFP</sup>* livers after HFD (Figure 2G), as their  
171 accumulation has been associated to apoptosis in hepatosteatosis [24]. Indeed,  
172 immunoblotting against cleaved Caspase3 confirmed that *Creld2<sup>eGFP/eGFP</sup>* livers after  
173 HFD underwent increased apoptosis when compared to *Creld2<sup>WT/WT</sup>* (Figure 2H, S1J).

174 Further, CoCena identified the darkgreen module, which contains genes being  
175 highly expressed after HFD diet, but which are globally downregulated in  
176 *Creld2<sup>eGFP/eGFP</sup>* livers when comparing them to *Creld2<sup>WT/WT</sup>* in each condition (Figure  
177 2E, Table S1). GO and Hallmark terms indicated that many of the 558 genes were  
178 involved in the regulation of lipid localization and transport. Among these genes were  
179 Apolipoprotein genes (*Apoa4*, *Apoc2*, *Apof*), which are important for lipid transport,  
180 genes involved in lipid distribution (*Abcd1*, *Ldlr*, *Osbpl3*, *Plscr2/4*, *Slco1b2*) and the

181 circadian rhythm regulating transcription factor *Cry2*, which is responsible for the  
182 orchestration of physiological metabolism (Figure 2F).

183 The steelblue module (459 genes) includes genes, which are upregulated in  
184 *Creld2<sup>eGFP/eGFP</sup>* animals during CD and HFD>CD recovery diets. Many of these genes  
185 are correlated to fatty acid (FA) metabolism, mostly involving genes for lipid catabolism  
186 (*Acot2*, *Ehhadh*, *Cyp4a10*, *Rdh16*) and some genes responsible for lipid anabolic  
187 processes (*Aldoa*, *Elovl5*) (Figure 2F), which may explain why *Creld2<sup>eGFP/eGFP</sup>* animals  
188 and livers show reduced lipid amounts as they upregulate these genes even more than  
189 *Creld2<sup>WT/WT</sup>* after HFD>CD recovery.

190 The pink module returned 557 genes that were downregulated in  
191 *Creld2<sup>eGFP/eGFP</sup>* livers when compared to controls, particularly in the HFD>CD  
192 condition. These genes were involved in 'responses to topologically incorrect protein',  
193 'protein processing in the ER' and the 'UPR' based on GO, KEGG and Hallmark  
194 enrichment analyses. Among these genes were chaperones and co-chaperones  
195 (*Dnajb9*, *Hspa8*, *Hsph1*, *Fkbp4*), including *Hspa5* (*Grp78*) (Figure 2F). We therefore  
196 investigated whether Grp78 expression and UPR activation were affected on the  
197 protein level. Yet, neither Grp78 nor phosphorylation levels of Perk and eIF2 $\alpha$  were  
198 significantly changed in *Creld2<sup>eGFP/eGFP</sup>* livers when compared to littermate controls,  
199 (Figure S1J, K). Further, the comparison of CD versus HFD groups per genotype did  
200 not reveal any sign of induced ER stress on transcript or protein level (Figure 2F, S1J-  
201 K), with Grp78 and Chop expression being even downregulated after HFD when  
202 compared to CD (Figure S1J-K). To test for other targets of the UPR that might be  
203 affected by the dietary change and that may have not been included in the CoCena<sup>2</sup>  
204 analysis, we additionally performed a direct pairwise comparison of differentially  
205 expressed genes (lfc = 1.32; p-value = 0.05) between CD or HFD in *Creld2<sup>WT/WT</sup>* or



206 *Creld2<sup>eGFP/eGFP</sup>* animals. None of these analyses returned genes involved in UPR  
207 (Table S2), indicating that 12 weeks of HFD do not induce ER stress in the liver.

208 Taken together, our data suggest that *Creld2<sup>eGFP/eGFP</sup>* animals can generally  
209 cope with an excess of lipid uptake for a short time period of 12 weeks, despite  
210 transcriptional changes that hint towards altered lipid metabolic processes.  
211 Furthermore, neither transcriptome nor protein expression analysis revealed a lipid-  
212 driven ER stress response in the liver, despite an enhanced apoptotic phenotype in  
213 *Creld2<sup>eGFP/eGFP</sup>* mice livers.

214

215 Next, we turned to the question whether *Creld2* is involved in the resolution of ER  
216 stress. To this end *Creld2<sup>eGFP/eGFP</sup>* animals and littermate controls received a single  
217 intraperitoneal injection of the ER stressor Tm (1 mg/kg) or sucrose as control since  
218 Tm was prepared in a sucrose solution (Figure 3A). Two days post injection, mice were  
219 analyzed for the extent of fatty liver development, which served as surrogate readout  
220 of unresolved ER stress (Figure 3B, C). Histological analyses as well as shotgun  
221 lipidomics indicated that *Creld2<sup>WT/WT</sup>* livers did not accumulate significant amounts of  
222 lipids or glycogen after Tm injection, while an increase of lipids after Tm injection could  
223 be observed in *Creld2<sup>eGFP/eGFP</sup>* livers (Figure 3B, C, S2A-B). The slightly increased lipid  
224 storage in *Creld2<sup>WT/WT</sup>* animals largely resulted from accumulation of cholesterol and  
225 cholesterol esters (Figure 3C). However, *Creld2<sup>eGFP/eGFP</sup>* livers stored significantly  
226 more lipids than *Creld2<sup>WT/WT</sup>* controls after Tm treatment, which could be mainly  
227 attributed to augmented TAG, DAG and cholesterol ester abundance (Figure 3B, C).  
228 This fatty liver phenotype was accompanied by a decreased PAS signal when  
229 compared to controls (Figure 3B, S2C). Further, MGT revealed an increased collagen  
230 abundance after Tm treatment in both genotypes (Figure S2D, E).

231 To identify the molecular mechanisms that lead to augmented lipid  
232 accumulation in *Creld2<sup>eGFP/eGFP</sup>* mice after ER-stress induction with Tm we performed  
233 RNA-seq on livers and analyzed the gene expression using principle component  
234 analysis (PCA, Figure S2F) and CoCena<sup>2</sup> (Figure 3D, Table S3). The maroon module  
235 (1308 genes) contains genes that were upregulated after Tm treatment in both  
236 genotypes when compared to untreated mice, however, with even a higher expression  
237 in *Creld2<sup>eGFP/eGFP</sup>* livers. GO, KEGG and Hallmark enrichment analyses returned terms  
238 such as ‘protein localization to ER’, ‘protein processing in ER’ and ‘UPR’ (Figure 3D),  
239 which comprised UPR- (*Hspa5*, *Hsp90b1*, *Ern1*) and ERAD-related genes (*Derl1*,  
240 *Edem1*, *Pdia3*, *Pdia4*, *Erlec1*) (Figure 3E). Tm treatment prevents protein  
241 glycosylation, which in turn induces ER stress and lipid accumulation [14] (Figure 3B,  
242 C). Wildtype livers largely recover from Tm-induced lipid perturbations after 2-3 days  
243 while keeping part of the UPR active, e.g. expression of chaperones Grp78 and Grp94  
244 (*Hsp90b1*) [14,21]. Our data validate these observations showing that UPR is active  
245 after 2 days of Tm treatment and further suggest that *Creld2<sup>eGFP/eGFP</sup>* livers undergo  
246 elevated ER stress when compared to *Creld2<sup>WT/WT</sup>* controls. In contrast, the  
247 darkorange module (123 genes) identified genes that are downregulated in  
248 *Creld2<sup>eGFP/eGFP</sup>* livers, and that also belong to the UPR (e.g. *Perk/Eif2ak3*) (Figure 3D,  
249 E). These two CoCena<sup>2</sup> modules suggest that *Creld2<sup>eGFP/eGFP</sup>* mice are only partly able  
250 to induce the UPR under ER stress, and, therefore, are incapable to properly resolve  
251 ongoing ER stress. This in turn results in increased hepatic lipid storage, supporting  
252 the active role of Creld2 during UPR and subsequent ER protein processing capacity.

253 In line with this hypothesis, the module orchid (1545 genes) classified genes  
254 that are downregulated after Tm treatment in both genotypes, with even stronger  
255 downregulation in *Creld2<sup>eGFP/eGFP</sup>* livers (Figure 3D). GO and KEGG enrichment  
256 analysis of genes in the orchid module included mainly terms related to ‘cellular lipid

257 catabolic process' as well as 'Ppar signaling pathway' (Figure 3D), indicating that  
258 *Creld2*-deficient livers store increased amount of lipids, due to insufficient lipid  
259 catabolism (*Abcd1*, *Abcd2*, *Abhd1*, *Acot8*, *Gba2*, *Ivd*, *Pla2g15*, *Plcg1*, *Ppara*, *Acaa1b*)  
260 and diminished lipid transport (*Apoa1*, *Apoa4*, *Apoc2*, *Apoc3*, *ApoE*) (Figure 3E).

261 The module darkgreen identified 356 genes that were globally downregulated  
262 in *Creld2*<sup>eGFP/eGFP</sup> livers, with highest differences after Tm treatment (Figure 3D). These  
263 genes enriched largely for 'response to peptide' and 'insulin resistance' as determined  
264 by GO and KEGG pathway enrichment analyses. Among enzymes regulating energy  
265 homeostasis were *Slc27a1*, *Gys1* and *Nr1h2* (insulin resistance) as well as *Usf1*, *Cry1*  
266 and *Slc2a8* (response to peptide), which collectively regulate lipid and glucose  
267 metabolism. In addition, expression of genes associated with signal transduction  
268 (*Pik3cd*, *Nfkb1a*) and regulation of cellular growth (*Ptpa*, *Inpp11*, *Csk*) is disrupted in  
269 *Creld2*<sup>eGFP/eGFP</sup> livers, exhibiting further aspects of *Creld2*-dependent regulatory  
270 processes (Figure 3E). Summarized, CoCena<sup>2</sup> analyses of Tm challenged livers reveal  
271 a *Creld2*-dependent dysregulation of genes important for the resolution of ER stress  
272 resulting in altered lipid and glucose metabolism, and cellular signaling processes in  
273 *Creld2*-deficient mice livers, which subsequently leads to increased lipid storage.

274 To test this hypothesis, we first analyzed Grp78 protein abundance after Tm  
275 treatment as an indicator for protein accumulation in the ER lumen. Similar to RNA-  
276 seq results, Grp78 was upregulated in wildtype animals after Tm when compared to  
277 control treatment, but was even more abundant in *Creld2*<sup>eGFP/eGFP</sup> livers (Figure 3F,  
278 S2G). Of note, both GFP expression in *Creld2*<sup>eGFP/eGFP</sup> and *Creld2* expression in  
279 *Creld2*<sup>WT/WT</sup> littermate controls was increased upon both treatment conditions (Figure  
280 3F, S2G), rendering *Creld2* expression and the *Creld2*<sup>WT/eGFP</sup> mouse as an efficient  
281 tool to monitor cellular stress. We next tested the activation of the Perk-axis via  
282 analysis of Perk and eIF2 $\alpha$  phosphorylation and Gadd34 protein abundance. Despite

283 the increased levels of Grp78, we did not detect enhanced activation of the Perk-axis  
284 in *Creld2<sup>eGFP/eGFP</sup>* livers (Figure 3F, S2G). In summary, induction of ER stress via Tm  
285 causes exacerbated ER stress in *Creld2<sup>eGFP/eGFP</sup>* mice, as indicated by increased  
286 Grp78 expression and consequently augmented hepatic lipid storage, supporting the  
287 notion that Creld2 is required to maintain tissue homeostasis in order to prevent lipid  
288 accumulation due to long-lasting and unresolved ER stress.

289

290 To investigate the molecular function of Creld2 in UPR and metabolic homeostasis we  
291 performed co-immunoprecipitation experiments by tandem affinity purification [25] and  
292 subsequent mass spectrometry. We used murine Creld2 tagged either at the N- or C-  
293 terminus to exclude inhibition of protein binding due to the fused Strep-Flag tag.  
294 Moreover, Creld2 constructs were either transiently expressed (72 h) or stably  
295 integrated into the genome of HEK239 cells (Figure 4A) to *i*) enable the  
296 characterization of specific interactions with chaperones, since a strong transient  
297 overexpression increases the unspecific co-purification of heat shock proteins [25] and  
298 *ii*) select for highly conserved interactions, which would also occur in this inter-species  
299 (mouse-human) setup. Using a stringent filtering pipeline and imputation for missing  
300 values (Figure 4B, see also methods), we found 31 putative interaction partners  
301 (Figure 4C, Table S4). Analysis for GO enrichment returned terms such as ‘response  
302 to ER stress’, ‘protein folding’, and ‘cell redox homeostasis’ (Figure 4D). Many  
303 chaperones and protein disulphide-isomerases (PDI) were present in the transient  
304 condition (C2-SF trans), some of which (HSPA8, HSP90B, HYOU1) have been  
305 previously proposed to interact with Creld2 [26]. However, since these proteins were  
306 not enriched in the stably transfected cells (FS-C2 stab and C2-SF stab) we propose  
307 that these represent unspecific co-purification products [25] underlining the constraints  
308 of co-immunoprecipitation assays in transiently transfected cell lines.

309 We thus focused our analysis on candidates present in at least 2 conditions.  
310 This led to the identification of Creld2 itself, as expected, as well as HSPA5 (GRP78),  
311 thioredoxin domain-containing 5 (TXNDC5) and glutathione S-transferase Mu3  
312 (GSTM3) as potent specific Creld2 binding partners (Figure 4C). Interaction with  
313 GRP78 [26] further endorses an active role of Creld2 in regulating UPR, as it may  
314 sequester the chaperone away from Perk/Atf6/Ire1, thereby, promoting the activation  
315 of the three UPR axes. TXNDC5, also known as endo PDI, is a thioredoxin peroxidase  
316 whose expression is regulated by ATF6 and sXBP1. Functionally it is proposed to  
317 reduce misfolded protein load [27]. Intriguingly, also Creld2 has been proposed to have  
318 PDI-like functions [26], hinting towards a synergistic mechanism between these  
319 proteins to resolve ER stress. GSTM3 is a member of the glutathione S-transferases  
320 superfamily that promotes detoxification of reactive oxygen species (ROS) [28].  
321 Oxidative stress and UPR are tightly interlinked, exemplified by PERK being upstream  
322 of the transcription factor NRF2 that counteracts the toxic effects of ROS produced  
323 upon ER stress during protein folding, e.g. via PDI activity [29]. Thus, the interaction  
324 of Creld2 with GSTM3 may represent an additional point of crosstalk between these  
325 cellular stresses. In summary, our data strengthen the hypothesis of an active  
326 involvement of Creld2 in UPR via interaction with chaperones and enzymes, whose  
327 activity is required to overcome cellular stress.

328

329 Overall, our data suggested that Creld2 function is required to maintain hepatic  
330 homeostasis under ER stress responses in mice. Therefore, we next asked whether  
331 human CRELD2 would play a role under pathophysiological conditions in the liver and  
332 analysed a cohort of 57 obese patients with varying severity of non-alcoholic fatty liver  
333 disease (NAFLD) and 4 controls for CRELD2 expression. We first divided patients into  
334 two groups - with or without non-alcoholic steatohepatitis (NASH) as diagnosed using

335 the SAF (Steatosis, Activity and Fibrosis) score, which increases with disease  
336 progression [30]. Intriguingly, both CRELD2 transcript and protein levels in the liver  
337 were significantly upregulated in male patients with NASH, while expression in female  
338 patients remained unaffected (Figure 5A). Control patients showed similar expression  
339 to NAFL patients. To test whether secreted CRELD2 could be used as a diagnostic  
340 marker for NAFLD severity we plotted the serum concentration of CRELD2 against the  
341 SAF score (Figure 5B). While no correlation was observed in female patients, males  
342 had an inverse correlation with low levels of CRELD2 at higher SAF scores, which may  
343 hint towards a retention mechanism for CRELD2 in the tissue during hepatic  
344 pathophysiology. In summary, CRELD2 shows a sex-specific function during NAFLD  
345 in humans with an intra-hepatic upregulation of CRELD2 expression, which seems to  
346 be associated with progression to NASH in male patients.

347

## 348 **Discussion**

349 Our study shows that *Creld2* plays an active role during UPR and contributes to the  
350 overall maintenance of cell homeostasis and resolution of ER stress. Using the newly  
351 generated *Creld2<sup>eGFP/eGFP</sup>* transgenic mouse model, we characterized the hepatic  
352 stress response of *Creld2*-deficient mice. *Creld2<sup>eGFP/eGFP</sup>* mice do not show gross  
353 phenotypic differences during steady state compared to wildtype controls. However,  
354 after challenge with Tm, *Creld2*-deficient livers show perturbed induction of UPR,  
355 which ultimately leads to dysregulated lipid and glucose metabolism resulting in  
356 exacerbated development of NAFLD. These findings are congruent with previous  
357 reports about *Atf6* knockout mice [15,21], suggesting the involvement of *Creld2* in  
358 regulating a proper response to ER stress downstream of *Atf6*. This is further  
359 evidenced by increased susceptibility of CRELD2-deficient Neuro2a cells to treatment  
360 with Tm [23].

361 Dysregulation of the UPR in *Creld2*-deficient livers is evident by increased  
362 expression of major UPR components, e.g. *Edem1*, *Ern1 (Ire1)* and *Hspa5*. At the  
363 same time they show decreased expression of *Perk* and *Perk* downstream target  
364 genes, such as *Herpud1* and *Hspa1a* [10,31], as well as *Syvn1*, which is induced by  
365 sXbp1 possibly in combined action with *Atf6* [32]. UPR dysregulation is accompanied  
366 by downregulated gene expression of important components for lipid transport and  
367 catabolism, energy metabolism and insulin signalling, which reportedly come along  
368 with an impaired ER stress response [14,33–35]. Thus, *Creld2*-deficient livers show  
369 overactive UPR but are unable to fully activate the gene expression programs of all  
370 three UPR branches. Since *Creld2* expression is induced by the *Atf6* pathway we  
371 hypothesized that *Creld2* is involved in the regulation of the *Atf6* axis. In fact, a majority  
372 of highly induced UPR genes in *Creld2*-deficient livers are *Atf6* target genes (*Calr*,  
373 *Pdia4*, *Pdia6*, *Hsp90b1*, *Hyou1*) [10]. Yet, *Creld2<sup>eGFP/eGFP</sup>* mice also display deficient  
374 induction of parts of the *Perk* and *Ire1* pathway on transcriptional level, suggesting that  
375 *Creld2* is involved in a cross-talk between the three UPR axes.

376 In contrast to pharmacological ER stress challenge, *Creld2<sup>eGFP/eGFP</sup>* mice fed  
377 with HFD display an ameliorated dietary induced obesity phenotype, hinting towards  
378 another layer of *Creld2* impact on organ function. In this model, *Creld2*-deficient mice  
379 reveal lower body weights and reduced liver steatosis. These findings are  
380 accompanied by downregulated expression of genes important for lipid localization and  
381 transport but increased expression of genes necessary for lipid catabolism, a process  
382 required for energy production from fatty acids. These observations indicate that  
383 *Creld2<sup>eGFP/eGFP</sup>* mice have a fundamentally higher energy expenditure. The underlying  
384 cause for the higher energy demand might be the upregulated expression of ribosomal  
385 genes, especially during HFD recovery (HFD>CD). Since the production of ribosomal  
386 proteins is a highly energy consuming process [36], *Creld2*-deficient mice may

387 upregulate ATP synthesis and, therefore, increase the utility and catabolism of lipids  
388 leading to the lower body weights and less accumulation of lipids in their livers as  
389 compared to littermate controls. Concomitantly, livers of *Creld2<sup>eGFP/eGFP</sup>* animals  
390 display reduced gene expression of UPR components in all conditions with lowest  
391 induction during HFD recovery. These observations can be linked to previous reports  
392 showing that perturbation of Perk downstream components eIF2 $\alpha$  [37] or Atf4 [38],  
393 lead to diminished hepatosteatosis during high-fat diet and leaner mice exhibiting  
394 increased energy expenditure, respectively. In addition, Perk inhibits the expression of  
395 ribosomal genes [31], hinting towards an impairment of Perk downstream targets in  
396 *Creld2*-deficient mice, which results in the upregulation of ribosomal genes followed by  
397 increased fatty acid catabolism for ATP production due to the increased energy  
398 demand in these mice.

399 Furthermore, we found no evidence that lipid accumulation through HFD *per se*  
400 induces UPR in wildtype or *Creld2<sup>eGFP/eGFP</sup>* livers. Yet, livers from *Creld2<sup>eGFP/eGFP</sup>*  
401 animals show first signs of cellular stress and apoptosis when compared to controls,  
402 which underlines the UPR-independent protective function of Creld2 upon oxidative  
403 stress and ceramide-mediated hepatotoxicity caused by HFD [39,40]. Further, the diet  
404 switch from HFD to CD did not promote ER-stress induction in both genotypes, but  
405 rather reduced the expression of chaperones in *Creld2<sup>eGFP/eGFP</sup>* livers. Thus, we  
406 conclude that UPR does not play a major role during diet-induced hepatic steatosis as  
407 long as this pathophysiology is reversible and did not progress to NASH. Taken  
408 together, our data support the hypothesis that Creld2 is required to protect cells against  
409 ongoing stress, although the cells retain the ability to partially compensate through  
410 other signalling pathways.

411 Analysis of Creld2 interaction partners further implicates an active role in  
412 regulating the UPR: Creld2 protein accumulates 48 h after induced ER stress and has



413 the capacity to bind to Grp78. This in turn, may have two effects *i)* Grp78 would be  
414 sequestered from Perk/Ire1/Atf6 and thereby these sensors would be activated or *ii)*  
415 Creld2 might act as a co-chaperone and aid Grp78 in protein folding. Further, Creld2  
416 binds to the endo PDI Txndc5 and glutathione S-transferase Gstm3, two proteins  
417 important for ER stress reduction [41,42] and ROS detoxification [43], respectively.  
418 Txndc5 was reported to be transcriptionally regulated by Atf6 and sXbp1 [27], which  
419 places Creld2 function at the intersection between protein folding processes and the  
420 three UPR axes. How binding to Creld2 influences the function of these proteins  
421 remains to be investigated. Nevertheless, based on our mouse work we propose that  
422 Creld2 has a dual role during steady state and cellular stress conditions: it maintains  
423 balanced basal and ER stress responsive UPR activation, probably by modulating the  
424 Perk- and Atf6-dependent axes through binding to Grp78, and at the same time it  
425 contributes to the reduction of misfolded proteins either through its own putative PDI  
426 activity or by promoting the PDI activity of Txndc5 and detoxification function of Gstm3.

427 In humans, the fundamental causes for NAFLD development can be of various  
428 nature. However, the progression to NASH and hepatocellular carcinoma (HCC) is  
429 associated with or driven by increased and unresolved ER stress [44,45]. Our CRELD2  
430 expression analyses in livers of human NAFLD patients provide evidence for the  
431 importance of CRELD2 in the amelioration and reversion of NASH. Intriguingly,  
432 increased liver CRELD2 levels and the negative correlation of serum CRELD2 with  
433 disease severity could only be observed in male patients, while females did not show  
434 any differences. Sex differences in NAFLD have been demonstrated in both, rodent  
435 models and in human disease, to be more prevalent in men and postmenopausal  
436 women compared to premenopausal women, which is mostly attributed to hormone  
437 homeostasis and visceral fat accumulation [46,47] (Figure 6). We therefore favor the  
438 hypothesis that the hepatic ER stress response is sex dependent and thus a risk factor

439 for the development of NAFLD and progression to NASH or HCC particularly in males.  
440 This is in line with our results showing that CRELD2 accumulates only in livers of male  
441 NASH patients, as well as a previous study demonstrating that kidneys of male mice  
442 are more susceptible to ER stress-induced acute kidney injury than those of females  
443 due to a testosterone-dependent mechanism [48]. Further, CRELD2 - among six other  
444 proteins that maintain ER homeostasis - was identified as an adverse prognostic  
445 biomarker for overall survival in HCC patients [49] underlining that elevated and  
446 unresolved ER stress can promote liver pathophysiology. Therefore, it will be essential  
447 to take the sexual dimorphism into account in the future when studying the contribution  
448 of ER stress to hepatic steatosis as well as in the course of NAFLD treatment with UPR  
449 modulating agents.

450

## 451 **Materials and methods**

### 452 **Mouse work**

453 For the generation of a conventional *Creld2*<sup>eGFP/eGFP</sup> mouse the open reading frame  
454 (ORF) of the *Creld2* gene was replaced by an enhanced green fluorescent protein  
455 (eGFP) and a neomycin resistance cassette (neoR) flanked by two FRT sites via  
456 homologous recombination. False positive ES cell clones were excluded by a  
457 diphtheria toxin A (DTA) cassette, which was introduced after the 3' homologous region  
458 of the targeting vector. Positive ES cell clones were selected by PCR against the neoR  
459 cassette and confirmed by southern blot via an internal and 5' external probe.  
460 Heterozygous *Creld2*<sup>WT/eGFP/neo</sup> offspring from blastocyst injections of positive ES cell  
461 clones were crossed with mice ubiquitously expressing FLP recombinase for excision  
462 of the neoR cassette. neoR deletion was confirmed by PCR. Mice were provided with  
463 standard chow and autoclaved water ad libitum. Genotyping primers: *Creld2* wt

464 genotype fw 5'-CCTGAGCTGTCCTTAGAAAGTTGCTAG-3', Creld2 ko genotype fw  
465 5'-GCCCGACAACCACTACCTGAGC-3', Creld2 genotype rev 5'-  
466 GGGGTTTCATGTCCATGGGCCAC-3'.

467 To induce hepatic UPR, 8-9 weeks-old male mice were administered with Tm  
468 (1 mg/kg in 150 mM sucrose) or a vehicle control sucrose solution (150 mM) via i.p.  
469 injection and sacrificed after 48 h.

470 For HFD experiments, male mice received standard chow until 6 weeks of age.  
471 Afterwards, standard chow was replaced by a control diet (CD; metabolizable energy:  
472 62 % from carbohydrates, 11 % from fat, 27 % from protein; ssniff EF D12450B\* mod.  
473 LS) for 2 weeks prior to the beginning of the experiment. Subsequently, 8-week-old  
474 mice were either fed with CD or HFD (metabolizable energy: 22 % from carbohydrates,  
475 54 % from fat, 24 % from protein; ssniff EF acc. D12492 (I) mod.) for 12 weeks or mice  
476 were kept on HFD for 8 weeks and CD for 4 weeks (HFD>CD). Mice were weighed  
477 once a week. For the determination of the Homeostatic model assessment of insulin  
478 resistance (HOMA-IR) [50], mice were fasted for 6 hours and blood was drawn from 8-  
479 week-old mice at the beginning of the feeding period and from mice being fed CD or  
480 HFD for 8 weeks. Blood samples were analysed for blood glucose using a glucose  
481 meter (Accu-Chek, Aviva) and blood serum insulin levels (Mouse Insulin Elisa kit,  
482 Thermo Scientific) according to the manufacturers' instructions. HOMA-IR indices  
483 were calculated using the formula: (Glucose (mg/ml) x Insulin( $\mu$ U/ml))/405.

484 
$$\frac{\text{Glucose (mg}^{ml^{-1}}) \times \text{Insulin (}\mu\text{U}^{ml^{-1}})}{405}$$

485 All mice were kept under standard SPF housing conditions according to the  
486 approved animal license 84-02.04.2014.A335 with a 12 h dark/light cycle. All animal  
487 experiments were approved by the government under the license 84-02.04.2017.A335

488

489 **Histological stainings**

490 For paraffin stains, tissues were fixed in 4% PFA (Thermo Scientific). After fixation,  
491 tissues were dehydrated, paraffin embedded and cut at a thickness of 5  $\mu$ m.  
492 Subsequently, sections were deparaffinized, rehydrated and stained with Hematoxylin  
493 followed by Eosin (VWR), PAS (Roth) or MGT (Merck) according to the manufacturer's  
494 protocol. After dehydration, tissues were mounted in Entellan. For Cryo-embedded  
495 (Tissue-Tek, Sakura) tissue stains, sections were fixed in 4% PFA and stained with  
496 freshly prepared oil-red-O (Sigma-Aldrich) working solution according to the  
497 manufacturer's instructions followed by mounting in Kaiser's glycerol gelatine (Merck).  
498 Quantitative analyses of PAS, MGT and ORO stainings were done using ImageJ2  
499 software. Scripts for quantifications are provided upon reasonable request.

500

#### 501 **qPCR**

502 RNA was isolated using the Nucleospin RNA II kit (Macherey & Nagel) according to  
503 the manufacturer's instructions and reverse transcribed into cDNA by using the  
504 QantiTect reverse transcription kit (Qiagen) according to the manufacturer's  
505 instructions. For qRT-PCR reactions, primer pairs (see Table S5) were mixed with  
506 cDNA and iQ SYBR<sup>®</sup>Green Supermix (Bio-Rad), and qRT-PCR was run on an iQs  
507 Real-Time PCR Detection System (Bio-Rad). *CRELD2* gene expression was  
508 normalized to the reference gene *HPRT* (hypoxanthine-guanine  
509 phosphoribosyltransferase). Relative gene expression was calculated from the  
510 threshold cycles in relation to the reference gene and controls without NAFLD.  
511 Reactions were performed on a CFX96 Touch qPCR System (Bio-Rad).

512

#### 513 **Library preparation for RNA sequencing**

514 mRNA was converted into libraries of double stranded cDNA molecules as a template  
515 for high throughput sequencing following the SMART-Seq2 protocol [51]. Shortly,

516 mRNA was primed for SMART reverse transcription from 5 ng of total RNA using poly-  
517 T oligos. cDNA was pre-amplified by SMART ISPCR. Fragmentation was performed  
518 using the Illumina Nextera XT kit, followed by PCR amplification and indexing. Size-  
519 selection and purification of library fragments with preferentially 300-400 bp in length  
520 was performed using SPRIbeads (Beckman-Coulter). The size-distribution of cDNA  
521 libraries was measured using the Agilent high sensitivity D5000 assay on a TapeStation  
522 4200 system (Agilent). cDNA libraries were quantified using a Qubit high sensitivity  
523 dsDNA assay. 75 bp single-end sequencing was performed on a NextSeq500 system  
524 using High Output v2.5 chemistry. Base calling from base call files, alignment to the  
525 *Mus musculus* reference genome mm10 from UCSC and file conversion to fastq files  
526 were achieved by Illumina standard pipeline scripts (STAR version, bcl2fastq2 v.2.20).

527

## 528 **RNA sequencing analysis**

529 Kallisto pseudo-alignment [52] was used to quantify abundances of transcripts - read  
530 counts - from the bulk RNA-seq data. The kallisto read counts were used as input to  
531 DESeq2 [53] for calculation of normalized signal and differential gene expression.  
532 Genes are excluded from the analysis where the total read count of all samples is less  
533 than 10. This pre-filtering step removes genes in which there are very few reads, in  
534 order to reduce the memory size, and to increase the speed of the calculation. The diet  
535 and drug induced ER-stress dataset then comprised 25308 and 23985 genes  
536 respectively. DESeq Dataset (dds) was created to store the read counts and the  
537 intermediate estimated quantities with a merged design formula consist of genotype  
538 (*CreId2*<sup>WT/WT</sup> or *CreId2*<sup>eGFP/eGFP</sup>) and condition (dietary or pharmacological).  
539 Regularized log transformations (rlog) were used for the downstream analysis  
540 (clustering). Rlog produces transformed data on the log<sub>2</sub> scale which has been  
541 normalized with respect to library size. Unwanted surrogate variables were estimated

542 and modelled via Surrogate Variable Analysis (SVA) [54] using the “leek” method. In  
543 the diet related experiment 4 surrogate variables (SV) were identified and modelled.  
544 For the pharmacologically-induced dataset 3 SVs were identified and modelled. For  
545 DE gene analysis of CD versus HFD conditions, lfc threshold was set to 1.32. and the  
546 p-value threshold to 0.05. The top 5000 variable genes were selected and used as an  
547 input for co-expressional network analysis using CoCena<sup>2</sup>  
548 (<https://github.com/UlasThomas/CoCena2>). Pearson correlation analysis was performed  
549 with correlational significance measure  $p < 0.05$ . For the diet-induced dataset 0.706  
550 and for the pharmacologically-induced dataset 0.659 was identified as correlation  
551 coefficient cut-off. Based on a greedy approach, Louvain community detecting  
552 algorithm [55] was used to cluster the genes of the diet-induced dataset based on  
553 expression pattern between the different conditions. For the pharmacologically-  
554 induced dataset the infomap community detection algorithm [56] was used. Clustering  
555 was repeated 100 times. Minimal number of genes per cluster was set to 50. Gene set  
556 enrichment analysis (GSEA) was performed on all cluster genes using the following  
557 knowledge-bases: Hallmark, Reactome, GO, KEGG and DO. ClusterProfiler package  
558 [57] was used for all GSEAs using default options with the respective correlation  
559 coefficient cut-off for each dataset. The prior mechanisms associated with the Co-Cena  
560 clusters were manually selected from the GSEA results based on prior knowledge.

561

### 562 **Thin layer chromatography**

563 Total lipids were extracted as described by Bligh and Dyer [58]. Livers were  
564 homogenized in ice cold H<sub>2</sub>O (50mg wet weight/ml) in a Precellys homogenizer  
565 (Peqlab Biotechnology, Germany). 3 ml of chloroform/methanol 1:2 (v:v) were added  
566 to 800  $\mu$ l homogenate and vortexed. 1 ml of chloroform was added to the mixture and  
567 vortexed prior to addition of 1 ml H<sub>2</sub>O and thoroughly vortexed. Mixture was centrifuged

568 at 1000 g for 5 min at RT and the lower solvent phase was recovered. Same volumes  
569 of the solvent phase were evaporated under nitrogen and lipids were resuspended in  
570 100  $\mu$ l of chloroform/methanol 1:1 (v:v) (Merck). Lipid extracts corresponding to 1 mg  
571 wet liver weight were applied onto HPTLC silica gel 60 plates (10 X 20 cm: Merck) and  
572 plates were developed in *n*-hexane/diethylether/acetic acid 70:30:5 (v/v/v) (Merck,  
573 Roth) in a developing chamber (CAMAG, Switzerland). Dried plates were soaked in  
574 charring solution (copper sulfate (CuSO<sub>4</sub>) 10% and phosphoric acid (H<sub>2</sub>PO<sub>4</sub>) 8%  
575 (Roth)) and heated to 180 °C for 5-10 min for lipid visualization.

576

### 577 **Lipid mass spectrometry**

578 Livers were homogenized in ddH<sub>2</sub>O at a concentration of 20 mg (wet weight)/ml using  
579 a Precellys homogenizer (Peqlab Biotechnolog). For lipid extraction, 50  $\mu$ l of the  
580 homogenate were added to 500  $\mu$ l of extraction mix (CHCl<sub>3</sub>/MeOH 1/5 containing  
581 internal standards: 210 pmol PE(31:1), 396 pmol PC(31:1), 98 pmol PS(31:1), 84 pmol  
582 PI(34:0) , 56 pmol PA(31:1), 51 pmol PG (28:0), 28 pmol CL(56:0), 39 pmol LPA (17:0),  
583 35 pmol LPC(17:1), 38 pmol LPE (17:0), 32 pmol Cer(17:0), 99 pmol SM(17:0), 55  
584 pmol GlcCer(12:0), 14 pmol GM3 (18:0-D3), 359 pmol TG(47:1), 111 pmol CE(17:1),  
585 64 pmol DG(31:1), 103 pmol MG(17:1), 724 pmol Chol(d6), 45 pmol Car(15:0)) were  
586 added and the sample sonicated for 2 min followed by centrifugation at 20000 g for 2  
587 min. The supernatant was collected into a new tube and 200  $\mu$ l chloroform and 800  $\mu$ l  
588 1% AcOH in water were added, the sample briefly shaken and centrifuged for 2 min at  
589 20000 g. The upper aqueous phase was removed and the entire lower phase  
590 transferred into a new tube and evaporated in the speed vac (45°C, 10 min). Spray  
591 buffer (500  $\mu$ l of 8/5/1 2-propanol/MeOH/water, 10 mM ammonium acetate) was  
592 added, the sample sonicated for 5 min and infused at 10  $\mu$ l/min into a Thermo Q  
593 Exactive Plus spectrometer equipped with the HESI II ion source for shotgun

594 lipidomics. MS1 spectra (resolution 280000) were recorded in 100 m/z windows from  
595 250 – 1200 m/z (pos.) and 200 – 1700 m/z (neg.) followed by recording MS/MS spectra  
596 (res. 70000) by data independent acquisition in 1 m/z windows from 200 – 1200 (pos.)  
597 and 200 – 1700 (neg.) m/z. Raw files were converted to .mzml files and imported into  
598 and analysed by LipidXplorer software using custom mfiql files to identify sample lipids  
599 and internal standards. For further data processing, absolute amounts were calculated  
600 using the internal standard intensities followed by calculation of mol% of the identified  
601 lipids.

602

### 603 **Tandem affinity purification of tagged Creld2**

604 HEK293 cells were electroporated with plasmid DNA pcDNA3.1/Zeo(+) (Addgene)  
605 containing only the Strep-Flag (SF)-tag (mock), N-terminally tagged Creld2 (FS-C2)  
606 where the tag was integrated after the signal peptide or C-terminally tagged Creld2  
607 (C2-SF). Gene blocks were used to clone the constructs (see Table S6). Primer used  
608 for cloning:

609 NheI-Kozak-mC2-SF-tag fw 5'-CTAGCTAGCGCCACCATGCACCTGCTGCTTGCA-  
610 3', 5'-Creld2-KpnI TATGGTACCTCACAAATCCTCACGGGAGGG-3',

611 KpnI-Flag rev 5'-TAGGGTACCTCACTTGTCGTCGTC-3',

612 NheI-SF-tag fw 5'-CTAGCTAGCATGGGTGGAGGTTCTGGA-3',

613 KpnI-SF-tag rev 5'-GGAGCTCTGGATGGTACCTCACTTGTC-3'.

614 Plasmids comprised a zeocin resistance cassette for selection. Cells transiently  
615 expressing C2-SF were harvested 72 h post electroporation for tandem-affinity-  
616 purification (TAP). For the generation of stably expressing cell lines plasmid DNA was  
617 linearized prior to electroporation and selected for stable expression by Zeocin (200  
618 µg/ml) resistance for 4 weeks with validation of construct expression via  
619 immunoblotting against Creld2 and Flag (data not shown). For TAP cells were



620 incubated on ice in freshly prepared, ice cold TAP-lysis buffer (1x Complete protease  
621 inhibitor (Roche), 1x Phosphate inhibitor cocktail (PIC) I (Sigma-Aldrich), 1x PIC II  
622 (Sigma-Aldrich), 0.5% NP40 in 1x TBS) for 20 min, centrifuged for 10 min at 10000 g  
623 at 4°C and supernatant was recovered. Subsequently, lysates were incubated with  
624 Strep-tactin Sepharose resin (IBA) for 2 h at 4°C on a rotation wheel. After incubation  
625 lysates were transferred onto Micro Bio-Spin columns (0.8 ml, BioRad), washed 3  
626 times with TAP-wash buffer (1x PIC I, 1x PIC II, 0.1% NP40 in 1x TBS) and incubated  
627 with TAP-elution buffer (50 µM Desthiobiotin (IBA) in 1x TBS) at 4°C for 10 min prior  
628 to elution by centrifugation at 100 g for 10 sec. Eluates were incubated with anti-Flag  
629 M2 resin (Sigma-Aldrich) for 2 h at 4°C on a rotation wheel, washed once with TAP-  
630 wash buffer, twice with TBS and eluted by incubating samples with Flag elution buffer  
631 (200 µg/ml Flag peptide (Sigma-Aldrich) in 1x TBS) for 10 min following centrifugation  
632 for 10 sec at 2000 g. TAPs were performed in triplicates from cells harvested on  
633 different days.

634

### 635 **Processing of TAP proteins for mass spectrometry and analysis**

636 Eluates were reduced with 10 mM Dithiothreitol (DTT) for 30 min at 56 °C followed by  
637 alkylation with 55 mM Chloroacetamide (CAA) for 30 min at RT in the dark.  
638 Subsequently, samples were boiled in laemmli buffer (1 x final concentration 2% SDS,  
639 2 µM DTT, 5% (v/v) Glycerol, 50 µM Tris-HCL (pH 6.8, 0.01% (w/v) Bromophenol blue)  
640 at 95 °C for 10 min and run for approx. 1 cm in a 10% SDS-PAGE gel to separate  
641 purified proteins from the Flag peptide used for elution. Gels were fixed in fixation buffer  
642 (45 % H<sub>2</sub>O, 45 % MeOH, 10 % Acetic acid) for 1 h at RT and stained (fixation buffer,  
643 0.05 % Coomassie-G250, filtered) for 1 h at RT followed by a first destaining in fixation  
644 buffer for 1 h prior to destaining O/N. Protein lanes were separated, cut into small  
645 pieces, washed twice with MS-wash buffer (50 mM Ammonium bicarbonate (ABC), 50

646 % Acetonitrile (ACN)) for 20 min, dehydrated with ACN for 10 min and dried in a speed  
647 vac for 20 min. Afterwards, samples were washed with 50 mM ABC for 15 min at RT  
648 and dehydration was repeated with speed vacuuming for 30 min. For in-gel-digest of  
649 proteins, gel pieces were soaked in digest solution (0,009 µg/µl Trypsin, 0,001 µg/µl  
650 LysC, 45 mM ABC) for 30 min at 4 °C, covered with 50 mM ABC and digested O/N at  
651 37 °C. Supernatants were recovered, gel pieces incubated in extraction buffer (30 %  
652 ACN, 3 % Trifluoroacetic acid (TFA)) for 20 min at RT, supernatants were recovered  
653 and proteins were extracted for another time from gel pieces by incubation in 100 %  
654 ACN for 20 min at RT with recovery of supernatants. The recovered supernatants of  
655 individual samples were pooled, organic solvents were evaporated in a speed vac,  
656 samples were acidified with Formic acid (1 % final concentration), stage tipped and  
657 subjected to mass spectrometry.

658

### 659 **TAP mass spectrometry**

660 Raw mass spectrometry data files were analysed using MaxQuant software (version  
661 1.6.0.16). Further analysis of quantitated proteins was done with Perseus software  
662 (version 1.5.5.3). Data was cleaned by filtering out of reverse proteins, proteins only  
663 identified by site and contaminants, and filtered for valid proteins label-free  
664 quantification (LFQ) values identified in at least 2 technical replicates in minimum 1  
665 condition. Further analysis of data was done using R software. Missing LFQ values  
666 were imputed using the DEP package (version 1.6.1) by firstly imputing of missing not  
667 at random (MNAR) values with 0, followed by a screen for falsely categorized MNAR  
668 values and re-imputation of missing at random (MAR) values using the k-nearest  
669 neighbors (knn) algorithm. For statistical analysis of differentially enriched (DE)  
670 proteins two-tailed t-test with unequal variance was applied to conditions containing  
671 Creld2 protein versus the respective mock control (acute or stable). Proteins with fold

672 change > 0 (Creld2 containing conditions versus mock control) and p-value < 0.1 were  
673 considered differentially enriched.

674

675

## 676 **Patients and ethics**

677 The study protocol conformed to the revised Declaration of Helsinki (Edinburgh, 2000)  
678 and was approved by the local Institutional Review Board (Ethik-Kommission am  
679 Universitätsklinikum Essen; file number 09-4252). All patients provided written  
680 informed consent for participation in the study before recruitment. Liver tissue and  
681 serum were collected from morbidly obese patients undergoing bariatric surgery. All  
682 enrolled patients underwent physical and ultrasound examinations, and a complete set  
683 of laboratory studies. Subjects reporting excessive alcohol consumption (>20 g/day for  
684 men or >10 g/day for women) and those with other known causes of secondary fatty  
685 liver disease (e.g., viral hepatitis, metabolic liver disease, toxic liver disease) were  
686 excluded from the study. Histological evaluation of NAFLD and classification as NAFL  
687 or NASH were performed by two experienced pathologists according to the method of  
688 Bedossa et al. (SAF score [30]).

689

## 690 **CRELD2 ELISA**

691 Serum CRELD2 levels were measured using a human CRELD2 Elisa kit (Ray Biotech)  
692 according to the manufacturers' instructions. **Immunoblotting**

693 Human tissue samples: Liver tissue was directly lysed for 30 min on ice with RIPA  
694 Lysis and Extraction Buffer (Thermo Scientific) containing protease inhibitor cocktail  
695 and phosphostop (Roche). After centrifugation at 13 000 g for 15 min at 4 °C, protein  
696 concentration in the supernatant was measured using Bradford's reagent (Bio-Rad).

697 Mouse tissue samples: Tissue was snap frozen in liquid N<sub>2</sub> and stored at -80 °C until  
698 usage. Tissue was homogenized in RIPA buffer containing PIC I and PIC II (Sigma-  
699 Aldrich) and Complete protease inhibitor (Roche) using a Precellys homogenizer and  
700 lysed for 30 min on ice. 10-20 µg of total protein were separated by SDS-PAGE and  
701 transferred onto a PVDF membrane (Immobilon-P transfer membranes 0.45 µm,  
702 Merck) via semi-dry blotting (Trans-Blot Turbo Transfer System, Bio-Rad). If not  
703 otherwise mentioned, membranes were incubated with antibodies diluted in TBST  
704 (0.1% Tween20) over night at 4°C on a rocker with the particular antibodies (see Table  
705 S7). Protein band intensities were acquired using ImageJ2. Proteins of one membrane  
706 were normalized to Actin and set relative to a wildtype control located on the  
707 membrane.

708

### 709 **Statistical analysis and reproducibility**

710 Data are shown as mean with individual values per mouse represented as circles,  
711 unless stated otherwise. Statistical significance was analysed with R using unpaired  
712 two-tailed t-tests, one-way and two-way ANOVA as indicated in the figure legends. The  
713 n value represents biological replicates. Significance was considered at  $P < 0.05$ .  
714 Experiments were repeated to ensure reproducibility of the observations. No statistical  
715 methods were used to predetermine sample size.

716

### 717 **Data availability**

718 Gene expression data are currently being deposited in the GEO database. Lipid mass  
719 spectrometry data are deposited in a Github repository  
720 <https://github.com/maccabaeus/Creld2-lipid-mass-spectrometry.git>). The data that  
721 support the findings of this study are available from the corresponding author upon  
722 reasonable request.

723

724 **Acknowledgements**

725 We thank Prof. Michael Hoch for his long-standing support of this project. We thank  
726 Thomas D. Rutkowski for feedback on the manuscript. We thank Cornelia Cygon and  
727 Melanie Thielisch for technical support, and Dr. Joachim Degen for help with the  
728 generation of *CreId2<sup>eGFP/eGFP</sup>* mice. We would like to thank Prof. Margarete Odenthal  
729 (Institute for Pathology, University Hospital Cologne), Prof. Hideo A. Baba und Martin  
730 Schlattjan (Institute for Pathology, University Hospital Essen), and Prof. Johannes  
731 Haybäck (Institute for Pathology, University Hospital Magdeburg) for histological  
732 preparation and assessments for the validation cohort. We also thank Prof.  
733 Niedergethmann (Department for General- and Visceral Surgery, Alfried Krupp  
734 Hospital, Essen, Germany) and Prof. Hasenberg (Helios Hospital Niederberg) for  
735 sample collection of the validation cohort. AC was funded by the DFG CA267/14-1.  
736 EM and JLS were funded by the DFG under Germany's Excellence Strategy EXC2151-  
737 390873048. EM is supported by the Daimler and Benz Foundation. This work was  
738 funded by the Fritz Thyssen foundation (to EM, Az.10.18.2.029MN).

739

740 **Competing interests**

741 The authors declare no competing interests

742

743 **Contributions**

744 EM and PK conceived the project. PK, EM, NB, AF, LB, FB performed experiments.  
745 PK, EM, NB, AF analyzed data. EM, PK, and RB supervised experiments and data  
746 analysis. TU and JLS provided help with RNA-seq experiments and the script for  
747 CoCena<sup>2</sup> analyses. CT helped with lipidomic analyses. JPS and AC assisted in  
748 interpretation of human results. EM and PK wrote the manuscript.

749

750 **References**

- 751 [1] Rupp PA, Fouad GT, Egelston CA, Reifsteck CA, Olson SB, Knosp WM, et al.  
752 Identification, genomic organization and mRNA expression of CRELD1, the  
753 founding member of a unique family of matricellular proteins. *Gene*  
754 2002;293:47–57.
- 755 [2] D’Alessandro M, Richard M, Stigloher C, Gache V, Boulin T, Richmond JE, et  
756 al. CRELD1 is an evolutionarily-conserved maturational enhancer of ionotropic  
757 acetylcholine receptors. *Elife* 2018;7. <https://doi.org/10.7554/eLife.39649>.
- 758 [3] Oh-hashii K, Kunieda R, Hirata Y, Kiuchi K. Biosynthesis and secretion of  
759 mouse cysteine-rich with EGF-like domains 2. *FEBS Lett* 2011;585:2481–7.  
760 <https://doi.org/10.1016/j.febslet.2011.06.029>.
- 761 [4] Mass E, Wachten D, Aschenbrenner AC, Voelzmann A, Hoch M. Murine  
762 Creld1 controls cardiac development through activation of calcineurin/NFATc1  
763 signaling. *Dev Cell* 2014;28. <https://doi.org/10.1016/j.devcel.2014.02.012>.
- 764 [5] Kim Y, Park S-J, Manson SR, Molina CAF, Kidd K, Thiessen-Philbrook H, et al.  
765 Elevated urinary CRELD2 is associated with endoplasmic reticulum stress–  
766 mediated kidney disease. *JCI Insight* 2017;2.  
767 <https://doi.org/10.1172/jci.insight.92896>.
- 768 [6] Chen M-F, Chang C-H, Yang L-Y, Hsieh P-H, Shih H-N, Ueng SWN, et al.  
769 Synovial fluid interleukin-16, interleukin-18, and CRELD2 as novel biomarkers  
770 of prosthetic joint infections. *Bone Joint Res* 2019;8:179–88.  
771 <https://doi.org/10.1302/2046-3758.84.BJR-2018-0291.R1>.
- 772 [7] Oh-hashii K, Koga H, Ikeda S, Shimada K, Hirata Y, Kiuchi K. CRELD2 is a  
773 novel endoplasmic reticulum stress-inducible gene. *Biochem Biophys Res*  
774 *Commun* 2009;387:504–10.

- 775 [8] Oh-Hashi K, Koga H, Ikeda S, Shimada K, Hirata Y, Kiuchi K. Role of an ER  
776 stress response element in regulating the bidirectional promoter of the mouse  
777 CRELD2 - ALG12 gene pair. *BMC Genomics* 2010;11:664.
- 778 [9] Adachi Y, Yamamoto K, Okada T, Yoshida H, Harada A, Mori K. ATF6 Is a  
779 Transcription Factor Specializing in the Regulation of Quality Control Proteins  
780 in the Endoplasmic Reticulum. *Cell Struct Funct* 2008;33:75–89.  
781 <https://doi.org/10.1247/csf.07044>.
- 782 [10] Adamson B, Norman TM, Jost M, Cho MY, Nuñez JK, Chen Y, et al. A  
783 Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic  
784 Dissection of the Unfolded Protein Response. *Cell* 2016;167:1867-1882.e21.  
785 <https://doi.org/10.1016/j.cell.2016.11.048>.
- 786 [11] Walter P, Ron D. The Unfolded Protein Response: From Stress Pathway to  
787 Homeostatic Regulation. *Science* (80- ) 2011;334:1081–6.  
788 <https://doi.org/10.1126/science.1209038>.
- 789 [12] Hetz C. The unfolded protein response: controlling cell fate decisions under ER  
790 stress and beyond. *Nat Rev Mol Cell Biol* 2012;13:89–102.  
791 <https://doi.org/10.1038/nrm3270>.
- 792 [13] Song MJ, Malhi H. The unfolded protein response and hepatic lipid metabolism  
793 in non alcoholic fatty liver disease. *Pharmacol Ther* 2019;203:107401.  
794 <https://doi.org/10.1016/j.pharmthera.2019.107401>.
- 795 [14] Rutkowski DT, Wu J, Back S-H, Callaghan MU, Ferris SP, Iqbal J, et al. UPR  
796 pathways combine to prevent hepatic steatosis caused by ER stress-mediated  
797 suppression of transcriptional master regulators. *Dev Cell* 2008;15:829–40.  
798 <https://doi.org/10.1016/j.devcel.2008.10.015>.
- 799 [15] Yamamoto K, Takahara K, Oyadomari S, Okada T, Sato T, Harada A, et al.  
800 Induction of liver steatosis and lipid droplet formation in ATF6 $\alpha$ -knockout mice

- 801           burdened with pharmacological endoplasmic reticulum stress. *Mol Biol Cell*  
802           2010;21:2975–86. <https://doi.org/10.1091/mbc.E09-02-0133>.
- 803 [16] DeZwaan-McCabe D, Sheldon RD, Gorecki MC, Guo D-F, Gansemer ER,  
804           Kaufman RJ, et al. ER Stress Inhibits Liver Fatty Acid Oxidation while  
805           Unmitigated Stress Leads to Anorexia-Induced Lipolysis and Both Liver and  
806           Kidney Steatosis. *Cell Rep* 2017;19:1794–806.  
807           <https://doi.org/10.1016/j.celrep.2017.05.020>.
- 808 [17] Fu S, Yang L, Li P, Hofmann O, Dicker L, Hide W, et al. Aberrant lipid  
809           metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum  
810           stress in obesity. *Nature* 2011;473:528–31.  
811           <https://doi.org/10.1038/nature09968>.
- 812 [18] Ozcan U, Cao Q, Yilmaz E, Lee A-H, Iwakoshi NN, Ozdelen E, et al.  
813           Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes.  
814           *Science* 2004;306:457–61. <https://doi.org/10.1126/science.1103160>.
- 815 [19] Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, et al.  
816           Chemical chaperones reduce ER stress and restore glucose homeostasis in a  
817           mouse model of type 2 diabetes. *Science* 2006;313:1137–40.  
818           <https://doi.org/10.1126/science.1128294>.
- 819 [20] Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, et al.  
820           GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation  
821           and reduces hepatic steatosis in mice. *J Clin Invest* 2009;119:1201–15.  
822           <https://doi.org/10.1172/JCI37007>.
- 823 [21] Wu J, Rutkowski DT, Dubois M, Swathirajan J, Saunders T, Wang J, et al.  
824           ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells  
825           from chronic stress. *Dev Cell* 2007;13:351–64.  
826           <https://doi.org/10.1016/j.devcel.2007.07.005>.




- 827 [22] Usui M, Yamaguchi S, Tanji Y, Tominaga R, Ishigaki Y, Fukumoto M, et al.  
828 Atf6 $\alpha$ -null mice are glucose intolerant due to pancreatic  $\beta$ -cell failure on a high-  
829 fat diet but partially resistant to diet-induced insulin resistance. *Metabolism*  
830 2012;61:1118–28. <https://doi.org/10.1016/j.metabol.2012.01.004>.
- 831 [23] Oh-Hashi K, Fujimura K, Norisada J, Hirata Y. Expression analysis and  
832 functional characterization of the mouse cysteine-rich with EGF-like domains 2.  
833 *Sci Rep* 2018;8:12236. <https://doi.org/10.1038/s41598-018-30362-4>.
- 834 [24] Kuipers EJ, Yang VW, Musso G, Cassader M, Paschetta E, Gambino R.  
835 REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND  
836 HEPATOLOGY Bioactive Lipid Species and Metabolic Pathways in  
837 Progression and Resolution of Nonalcoholic Steatohepatitis 2018.  
838 <https://doi.org/10.1053/j.gastro.2018.06.031>.
- 839 [25] Gloeckner CJ, Boldt K, Schumacher A, Ueffing M. Tandem affinity purification  
840 of protein complexes from mammalian cells by the Strep/FLAG (SF)-TAP tag.  
841 *Methods Mol Biol* 2009;564:359–72. [https://doi.org/10.1007/978-1-60761-157-](https://doi.org/10.1007/978-1-60761-157-8_21)  
842 [8\\_21](https://doi.org/10.1007/978-1-60761-157-8_21).
- 843 [26] Hartley CL, Edwards S, Mullan L, Bell P a, Fresquet M, Boot-Handford RP, et  
844 al. Armet/Manf and Creld2 are components of a specialized ER stress  
845 response provoked by inappropriate formation of disulphide bonds: implications  
846 for genetic skeletal diseases. *Hum Mol Genet* 2013;22:5262–75.  
847 <https://doi.org/10.1093/hmg/ddt383>.
- 848 [27] Horna-Terrón E, Pradilla-Dieste A, Sánchez-de-Diego C, Osada J. TXNDC5, a  
849 newly discovered disulfide isomerase with a key role in cell physiology and  
850 pathology. *Int J Mol Sci* 2014;15:23501–18.  
851 <https://doi.org/10.3390/ijms151223501>.
- 852 [28] Board PG, Menon D. Glutathione transferases, regulators of cellular

- 853 metabolism and physiology. *Biochim Biophys Acta - Gen Subj*
- 854 2013;1830:3267–88. <https://doi.org/10.1016/J.BBAGEN.2012.11.019>.
- 855 [29] Zhang Z, Zhang L, Zhou L, Lei Y, Zhang Y, Huang C. Redox signaling and
- 856 unfolded protein response coordinate cell fate decisions under ER stress.
- 857 *Redox Biol* 2018. <https://doi.org/10.1016/J.REDOX.2018.11.005>.
- 858 [30] Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, et al.
- 859 Histopathological algorithm and scoring system for evaluation of liver lesions in
- 860 morbidly obese patients. *Hepatology* 2012;56:1751–9.
- 861 <https://doi.org/10.1002/hep.25889>.
- 862 [31] Gonen N, Sabath N, Burge CB, Shalgi R. Widespread PERK-dependent
- 863 repression of ER targets in response to ER stress. *Sci Rep* 2019;9:1–12.
- 864 <https://doi.org/10.1038/s41598-019-38705-5>.
- 865 [32] Savic S, Ouboussad L, Dickie LJ, Geiler J, Wong C, Doody GM, et al. TLR
- 866 dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis
- 867 synoviocytes. *J Autoimmun* 2014;50:59–66.
- 868 <https://doi.org/10.1016/j.jaut.2013.11.002>.
- 869 [33] Han J, Kaufman RJ. The role of ER stress in lipid metabolism and lipotoxicity. *J*
- 870 *Lipid Res* 2016;57:1329–38. <https://doi.org/10.1194/jlr.R067595>.
- 871 [34] Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. *J Hepatol*
- 872 2011;54:795–809. <https://doi.org/10.1016/j.jhep.2010.11.005>.
- 873 [35] Zhang K, Wang S, Malhotra J, Hassler JR, Back SH, Wang G, et al. The
- 874 unfolded protein response transducer IRE1 $\alpha$  prevents ER stress-induced
- 875 hepatic steatosis. *EMBO J* 2011;30:1357–75.
- 876 <https://doi.org/10.1038/emboj.2011.52>.
- 877 [36] Strunk BS, Karbstein K. Powering through ribosome assembly. *RNA*
- 878 2009;15:2083–104. <https://doi.org/10.1261/rna.1792109>.

- 879 [37] Oyadomari S, Harding HP, Zhang Y, Oyadomari M, Ron D. Dephosphorylation  
880 of Translation Initiation Factor 2 $\alpha$  Enhances Glucose Tolerance and Attenuates  
881 Hepatosteatosis in Mice. *Cell Metab* 2008;7:520–32.  
882 <https://doi.org/10.1016/j.cmet.2008.04.011>.
- 883 [38] Wang C, Huang Z, Du Y, Cheng Y, Chen S, Guo F. ATF4 regulates lipid  
884 metabolism and thermogenesis. *Cell Res* 2010;20:174–84.  
885 <https://doi.org/10.1038/cr.2010.4>.
- 886 [39] Longato L, Tong M, Wands JR, de la Monte SM. High fat diet induced hepatic  
887 steatosis and insulin resistance: Role of dysregulated ceramide metabolism.  
888 *Hepatol Res* 2012;42:412–27. [https://doi.org/10.1111/j.1872-](https://doi.org/10.1111/j.1872-034X.2011.00934.x)  
889 [034X.2011.00934.x](https://doi.org/10.1111/j.1872-034X.2011.00934.x).
- 890 [40] Kurek K, Piotrowska DM, Wiesiołek-Kurek P, Łukaszuk B, Chabowski A,  
891 Górski J, et al. Inhibition of ceramide de novo synthesis reduces liver lipid  
892 accumulation in rats with nonalcoholic fatty liver disease. *Liver Int*  
893 2014;34:1074–83. <https://doi.org/10.1111/liv.12331>.
- 894 [41] Alberti A, Karamessinis P, Peroulis M, Kypreou K, Kavvadas P, Pagakis S, et  
895 al. ERp46 is reduced by high glucose and regulates insulin content in  
896 pancreatic  $\beta$ -cells. *Am J Physiol Metab* 2009;297:E812–21.  
897 <https://doi.org/10.1152/ajpendo.00053.2009>.
- 898 [42] Chen DL, Xiang JN, Yang LY. Role of ERp46 in  $\beta$ -cell lipoapoptosis through  
899 endoplasmic reticulum stress pathway as well as the protective effect of  
900 exendin-4. *Biochem Biophys Res Commun* 2012;426:324–9.  
901 <https://doi.org/10.1016/j.bbrc.2012.08.072>.
- 902 [43] Wang S, Yang J, Ding C, Li J, You L, Dai M, et al. Glutathione S-Transferase  
903 Mu-3 Predicts a Better Prognosis and Inhibits Malignant Behavior and  
904 Glycolysis in Pancreatic Cancer. *Front Oncol* 2020;10:1539.


- 905 <https://doi.org/10.3389/fonc.2020.01539>.
- 906 [44] Maiers JL, Malhi H. Endoplasmic Reticulum Stress in Metabolic Liver Diseases  
907 and Hepatic Fibrosis. *Semin Liver Dis* 2019;39:235–48.  
908 <https://doi.org/10.1055/s-0039-1681032>.
- 909 [45] Reibe S, Febbraio MA. Relieving ER stress to target NASH-driven  
910 hepatocellular carcinoma. *Nat Rev Endocrinol* 2019;15:73–4.  
911 <https://doi.org/10.1038/s41574-018-0145-7>.
- 912 [46] Lonardo A, Suzuki A. Nonalcoholic fatty liver disease: does sex matter?  
913 *HepatoBiliary Surg Nutr* 2019;8:164–6.  
914 <https://doi.org/10.21037/hbsn.2018.12.04>.
- 915 [47] Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A.  
916 NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive  
917 Status in the Development and Progression of Nonalcoholic Fatty Liver  
918 Disease and Inherent Cardiovascular Risk. *Adv Ther* 2017;34:1291–326.  
919 <https://doi.org/10.1007/s12325-017-0556-1>.
- 920 [48] Hodeify R, Megyesi J, Tarcsafalvi A, Mustafa HI, Hti Lar Seng NS, Price PM.  
921 Gender differences control the susceptibility to ER stress-induced acute kidney  
922 injury. *Am J Physiol - Ren Physiol* 2013;304.  
923 <https://doi.org/10.1152/ajprenal.00590.2012>.
- 924 [49] Liu G-M, Zeng H-D, Zhang C-Y, Xu J-W. Key genes associated with diabetes  
925 mellitus and hepatocellular carcinoma. *Pathol - Res Pract* 2019:152510.  
926 <https://doi.org/10.1016/j.prp.2019.152510>.
- 927 [50] Matthews DR, Hosker JP, Rudenski a S, Naylor B a, Treacher DF, Turner RC.  
928 Homeostasis model assessment: insulin resistance and beta-cell function from  
929 fasting plasma glucose and insulin concentrations in man. *Diabetologia*  
930 1985;28:412–9. <https://doi.org/10.1007/BF00280883>.

- 931 [51] Picelli S, Bjorklund AK, Faridani OR, Sagasser S, Winberg G, Sandberg R.  
932 Smart-seq2 for sensitive full-length transcriptome profiling in single cells. *Nat*  
933 *Methods* 2013;10:1096–8. <https://doi.org/10.1038/nmeth.2639>.
- 934 [52] Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq  
935 quantification. *Nat Biotechnol* 2016;34:525–7. <https://doi.org/10.1038/nbt.3519>.
- 936 [53] Love MI, Huber W, Anders S. Moderated estimation of fold change and  
937 dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.  
938 <https://doi.org/10.1186/s13059-014-0550-8>.
- 939 [54] Leek J, Johnson W, Parker H, Fertig E, Jaffe A, Storey J, et al. sva: Surrogate  
940 Variable Analysis. R package version 3.34.0. 2019.
- 941 [55] Blondel VD, Guillaume JL, Lambiotte R, Lefebvre E. Fast unfolding of  
942 communities in large networks. *J Stat Mech Theory Exp* 2008;2008.  
943 <https://doi.org/10.1088/1742-5468/2008/10/P10008>.
- 944 [56] Rosvall M, Bergstrom CT. Maps of random walks on complex networks reveal  
945 community structure. *Proc Natl Acad Sci U S A* 2008;105:1118–23.  
946 <https://doi.org/10.1073/pnas.0706851105>.
- 947 [57] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing  
948 biological themes among gene clusters. *OMICS* 2012;16:284–7.  
949 <https://doi.org/10.1089/omi.2011.0118>.
- 950 [58] BLIGH EG, DYER WJ. A rapid method of total lipid extraction and purification.  
951 *Can J Biochem Physiol* 1959;37:911–7. <https://doi.org/10.1139/o59-099>.
- 952




**Figure 1: Generation and phenotypic analysis of the *Creld2*eGFP/eGFP mouse. (A)**

Gene targeting strategy. The complete genetic locus of *Creld2* was replaced by an eGFP reporter cassette via homologous recombination. The targeting vector comprised a neoR cassette flanked by FRT sites for positive ES cell selection. Following recombination, the neoR cassette was excised by FLP-mediated deletion. Primers for ES cell screening (gt2\_fw, gt2\_rv, neo\_fw) and probes used for Southern blotting (5' probe, internal probe) and the resulting fragment lengths (bp) are indicated. **(B)** Tissue expression profile of *Creld2* and testing of the anti-*Creld2* antibody specificity by immunoblotting. Arrowheads indicate unspecific protein bands. **(C)** Animals born from *Creld2* WT/GFP x *Creld2* WT/GFP matings. **(D)** Body weight of males (1 month: n = 5-7 and 2 months: n = 44-50). Error bars represent  $\pm$  SD. **(E)** Liver weight of males (2 months: n = 5). Unpaired two-tailed t-test. **(F)** Histological analysis of liver by hematoxylin-eosin (HE) and Masson Goldner trichrome (MGT) in young *Creld2*eGFP/eGFP and wildtype mice. Representative for n = 8-10.



**Figure 2: Tissue and molecular response of *Credl2*<sup>eGFP/eGFP</sup> mice to high-fat diet.**


(A) Experimental setup. (B) Body weight of male mice fed with CD (control diet; n = 13-14) and HFD (high-fat diet; n = 12-31) for 12 weeks, or HFD for 8 weeks following CD for 4 weeks (n = 14-19). (C) Analysis of insulin resistance induction by HFD via HOMA-IR (homeostatic model assessment of insulin resistance, CD start: n = 22-29; CD 8 weeks: n = 7-10; HFD 8 weeks: n = 17-20). One-way ANOVA with Tukey post-hoc test. (D) Lipid mass spectrometry of livers (n = 5 per condition). DAG: Diacylglycerol. TAG: Triacylglycerol. Circles represent individual mice. One-way ANOVA. (E) Co-expression network analysis (CoCena) performed on RNA-seq data of livers (n = 5 per condition). Numbers indicate genes belonging to a module. Colours represent cluster names: pink: 557 genes, indianred: 64 genes, darkgreen: 558 genes, darkgrey: 73 genes, orchid: 65 genes, maroon: 141 genes, darkorange: 87 genes, steelblue: 459 genes, gold: 721 genes. GFC: group fold change. (F) Heatmap representation of selected genes from (E), values are displayed as z scores. (G) Lipid mass spectrometry analysis for ceramides. Circles represent individual mice. One-way ANOVA with Tukey post-hoc test. (H) Western blot analysis for cleaved Caspase 3 (n = 5). Circles represent individual mice. Unpaired two-tailed t-test. \* p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001, \*\*\*\* p < 0.0001.




**Figure 3: Tissue and molecular response of *Credl2*<sup>eGFP/eGFP</sup> mice to pharmacological ER stress induction. (A) Experimental setup. (B) Quantification of liver PAS stainings and mass spectrometrical assessment of liver lipids (n = 5 per condition). Circles represent individual mice. One-way ANOVA with Tukey post-hoc test. (C) Lipid mass spectrometry of livers (n = 5 per condition). DAG: Diacylglycerol. TAG: Triacylglycerol. CE: Cholesteryl esters. Circles represent individual mice. One-way ANOVA with Tukey post-hoc test. (D) Co-expression network analysis (CoCena) performed on RNA-seq data of livers (n = 5 per condition). Numbers indicate genes belonging to a module. Colours represent cluster names: orchid: 1545 genes, darkgrey: 121 genes, gold: 105 genes, darkorange: 123 genes, darkgreen: 356 genes, maroon: 1308 genes. GFC: group fold change. (E) Heatmap representation of selected genes from (D), values are displayed as z scores. (F) Western blot analysis for UPR components (n = 5 per condition). For Perk and eIF2 $\alpha$ , ratios of phosphorylated (P-Perk and P-eIF2 $\alpha$ ) and unphosphorylated protein abundance are displayed. Circles represent individual mice. One-way ANOVA with Tukey post-hoc test. \* p < 0.05; \*\* p < 0.01; \*\*\* p < 0.001, \*\*\*\* p < 0.0001.**




A



B




C




D

GO term	qValue
protein folding	2.04E-9
response to ER stress	4.58E-4
cell redox homeostasis	4.58E-4


**Figure 4: Creld2 interacts with proteins involved in protein folding, response to ER stress and detoxification. (A)** Schematic representation of constructs and expression conditions used for tandem-affinity-purification of tagged murine Creld2. **(B)** Workflow chart for analysis of mass spectrometry data. MNAR values in the dataset were first imputed by 0, followed MAR imputation by knn algorithm. MNAR: missing not at random; MAR: missing at random; knn: k-nearest neighbours. **(C)** Enriched Creld2 interaction partners across the different expression conditions. **(D)** Top three enriched GO terms resulting from enrichment analysis of all co-purified proteins.



**Figure 5: Hepatic CRELD2 expression increases in patients with non-alcoholic steatohepatitis. (A)** Hepatic gene and protein expression levels of CRELD2 in male (♂) and female (♀) non-alcoholic fatty liver disease (NAFLD) patients (grey circles) with or without NASH (non-alcoholic steatohepatitis) and healthy controls (green circles). Cohort is comprised of 57 patients. Circles represent individual patients. Unpaired two-tailed t-test. **(B)** Analysis of CRELD2 serum concentration in male (♂) and female (♀) patients plotted against the Steatosis Activity and Fibrosis (SAF) score (cohort comprised of 40 patients). Linear regression model.




**Figure 6: Graphical summary of Creld2 function.** Summarizing schematic of Creld2 functionality, PDI: protein disulfide isomerase; ROS: reactive oxygen species.



**Supplemental Figure 1: Diet-induced hepatosteatosis and analysis of liver**

**damage.** (A) Liver (n = 12-19) and eWAT (epididymal white adipose tissue, n = 9-14) weights of mice after 12 weeks of diet. (B-G) Representative histological analyses of livers from mice on different diets by (B) ORO (oil-red-O), (D) PAS (Periodic Acid Schiff) and (F) MGT (Masson Goldner trichrome) staining and their corresponding quantification (C, E, G). (H) Determination of liver damage by serum alanine aminotransferase (ALT) concentration. Circles represent individual mice (C, E, G, H). Scale bars represent 100 μm (B, D, F). (I) Principle component analysis of liver RNA-seq data shown in Figure 2. (J) Representative immunoblots of liver protein lysates on different diets. Refers to main Figure 2H for cleaved Caspase 3. (K) Western blot quantification of UPR components (n = 5) from (J). For Perk and eIF2α, ratios of phosphorylated (P-Perk and P-eIF2α) and unphosphorylated protein abundance are displayed. Circles represent individual mice.



**Supplemental Figure 2: Pharmacologically induced hepatosteatosis and analysis of liver damage. (A)** ORO (oil-red-O) staining of livers from ER stress induced mice (Ctrl: Sucrose control; Tm: Tunicamycin) and **(B)** ORO staining quantification. **(C)** PAS (Periodic Acid Schiff) staining. For PAS signal intensity quantification see Figure 3B. **(D, E)** MGT (Masson Goldner trichrome) staining and quantification. Circles represent individual mice (B, E). Scale bars represent 100  $\mu$ m. **(F)** Principle component analysis of liver RNA-seq data shown in Figure 3. **(G)** Representative immunoblots of liver protein lysates injected with sucrose control (Ctrl) or Tm (tunicamycin). Refers to main Figure 3F.